Microbot Medical Inc. (MBOT) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Microbot Medical Inc. is a medical device company developing the LIBERTY® Endovascular Robotic System, a fully disposable robot for endovascular procedures. The company operates as a single segment focused on the research, design, and development of robotic endoluminal surgery devices. As of the filing date, the company is a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $105,000 | $0 |
| Cost of Revenues | ($103,000) | $0 |
| Gross Profit | $2,000 | $0 |
| Operating Loss | ($4,320,000) | ($3,021,000) |
| Net Loss | ($3,671,000) | ($2,601,000) |
| Net Loss Per Share (Basic/Diluted) | ($0.05) | ($0.08) |
| Cash and Cash Equivalents | $3,657,000 | $3,912,000 |
| Marketable Securities | $68,843,000 | $74,680,000 |
| Total Assets | $78,066,000 | $81,544,000 |
| Total Liabilities | $3,961,000 | $3,990,000 |
| Shareholders' Equity | $74,105,000 | $77,554,000 |
Liquidity: As of March 31, 2026, the company held approximately $72.5 million in cash equivalents and marketable securities (excluding restricted cash). Management believes these funds are sufficient to operate for more than twelve months from the filing date.
Material Changes vs. Prior Period
- Revenue Generation: The company recorded $105,000 in revenue in Q1 2026, compared to zero in Q1 2025. This marks the beginning of commercial sales following the Limited Market Release of the LIBERTY® system in late 2025.
- Operating Expenses: Sales, General, and Administrative (SG&A) expenses increased significantly to $3.0 million from $1.6 million, driven by new hires, salary increases, and expanded commercialization activities. Research and Development (R&D) expenses decreased to $1.3 million from $1.5 million, largely due to increased government grants and the capitalization of manufacturing costs into inventory.
- Financing Income: Financing income rose to $649,000 from $104,000, attributed to higher interest income from short-term investments following capital raises in 2025.
- Inventory Build-up: Inventory increased from $584,000 to $2.3 million as the company ramped up manufacturing for commercial sale post-FDA clearance.
Outlook, Risks, and Management Commentary
- Commercialization: The company commenced its Full Market Release in April 2026, following a Limited Market Release in select high-volume regions during Q1. The company anticipates continued net losses as it scales manufacturing and commercialization.
- Regulatory Milestones: The company received FDA 510(k) clearance in September 2025 and ISO 13485:2016 certification in August 2024. CE Mark approval is anticipated in the second half of 2026.
- Geopolitical Risks: The company's R&D and operations are primarily based in Israel. The filing details significant risks related to the ongoing regional armed conflict involving Israel, Iran, and the United States. Risks include supply chain disruptions, workforce mobilization, airspace closures, and potential boycotts. While no material adverse effect has been recorded to date, the situation remains fluid.
- Capital Needs: The company intends to raise additional funds through debt or equity issuances, including its At-the-Market (ATM) facility, to fund growth. Future financing may result in shareholder dilution.
- Legal Proceedings: The company successfully concluded litigation against Alliance Investment Management and Joseph Mona, receiving a judgment of approximately $316,000 in Q1 2025. An employment-related charge filed in late 2025 was dismissed by the MCAD/EEOC in May 2026, with the company challenging the merits of the allegations.
Investor Verification Checklist
- Revenue Sustainability: Verify the volume and pricing of the initial $105,000 in revenue and the trajectory of the Full Market Release launched in April 2026.
- Cash Burn Rate: Monitor the quarterly cash burn rate against the $72.5 million liquidity position to confirm the "more than 12 months" runway assertion.
- Geopolitical Impact: Assess any emerging supply chain disruptions or operational delays in Israel due to the ongoing regional conflict.
- CE Mark Approval: Track progress toward the anticipated H2 2026 CE Mark approval for European market access.
- Dilution Risk: Review the terms of outstanding preferred investment options (Series F through J) and the utilization of the ATM facility for potential future dilution.